Vaccines based on Moderna and Pfizer/BioNTech’s mRNA technology have effectively promoted the fight against the COVID-19 pandemic and have great potential in preventing other dangerous diseases.
In the context of the COVID-19 pandemic, a major achievement in the medical field is the collaboration of scientists from all over the world to create many effective COVID-19 vaccines worldwide. Less than 1 year.
The most prominent of these are Hyundai Pharmaceuticals (USA) and Pfizer Pharmaceuticals (USA)/BioNTech (Germany), which have launched vaccines based on mRNA technology to inject vitality into the fight against the new coronavirus pandemic. -19…
With such impressive results, scientists expect mRNA vaccines to have great potential in preventing dangerous diseases such as HIV, cancer or influenza.
Messenger RNA (mRNA) vaccines “teach” cells how to make proteins that trigger the body’s immune response. By injecting synthetic mRNA, human cells become an on-demand vaccine factory, producing any protein that we want the immune system to learn to recognize and destroy.
This technology has been and is being studied for the treatment of other diseases.
Earlier this month, scientists at Yale University (USA) created a prototype mRNA vaccine that can “train” the guinea pig’s immune system to recognize and prevent tick-borne diseases, thereby protecting guinea pigs from tick-borne diseases. Fights the protein present in tick saliva.
They hope that if further developed, this vaccine can be used to help people avoid Lyme disease caused by fleas. However, this is just one example of the potential of mRNA vaccines.
In terms of the potential to change the world, mRNA vaccines have two key characteristics: rapid production, as evidenced by the record launch times of Pfizer/BioNTech and Moderna, and very unique characteristics. flexible. As the American Association of Medical Colleges (AAMC) pointed out in March, vaccine mRNA technology has the potential to treat diseases such as malaria and cystic fibrosis, tuberculosis, and hepatitis B.